Speaker Profile

Ph.D., Professor, The University of Iowa, President, SynderBio

Biography
Dr. Henry’s research focuses on the molecular and cellular basis of cancer progression and metastasis in order to develop new methods for its diagnosis and treatment. His laboratory made the initial discovery that malignant cancer cells are resistant to brief pulses of fluid shear stress. Since then he has been exploring both the biological significance and practical applications of this finding. His work on both the mechanism and diagnostic potential of this finding as it relates to circulating tumor cells has been funded by the Department of Defense and the National Cancer Institute, including a Provocative Questions R21 grant. Dr. Henry has over 25 years of experience in cancer research in both academic and industry settings, serving as senior scientist with Millennium Pharmaceuticals prior to his current academic positions.


Clinical & Research Tools:
SynderBio

SynderBio is a life science instrumentation and diagnostic company that offers novel techniques to expedite and enhance cancer diagnosis and research efforts using our novel, targeted cell separation technology.

SynderBio's Rapid Cell Separation Technology For CancerDx
SynderBio has a unique approach to improving biopsy/sample clean-up that is significantly faster and greatly outperforms the competition in terms of yield, enrichment, and purity of the resulting sample. SynderBio has demonstrated consistent, effective sample preparation in a range of cancer cell types, outperforming FACS and MACS and disaggregating cell clusters while eliminating dead/dying cells to maximize retention of scarce clinical samples.

 Session Abstract – PMWC Silicon Valley


The PMWC 2020 Clinical & Research Tools Showcase will provide a 15-minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.